Abstract
The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Infectious Disorders - Drug Targets
Title: Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Volume: 8 Issue: 3
Author(s): Yuping Lai and Richard L. Gallo
Affiliation:
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Abstract: The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Export Options
About this article
Cite this article as:
Lai Yuping and Gallo L. Richard, Toll-Like Receptors in Skin Infections and Inflammatory Diseases, Infectious Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/1871526510808030144
DOI https://dx.doi.org/10.2174/1871526510808030144 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Prevalence of Dilated Cardiomyopathy in HIV-Infected African Patients Not Receiving HAART: A Multicenter, Observational, Prospective, Cohort Study in Rwanda
Current HIV Research Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews Riboswitches as Potential Targets for the Development of Anti-Biofilm Drugs
Current Topics in Medicinal Chemistry Plant-Derived Products as Antibacterial and Antifungal Agents in Human Health Care
Current Medicinal Chemistry Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Exploring the Biology and Structural Architecture of Sortase Role on Biofilm Formation in Gram Positive Pathogens
Current Topics in Medicinal Chemistry Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Current Respiratory Medicine Reviews Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets New Synthetic Antibiotics for the Treatment of Enterococcus and Campylobacter Infection
Current Topics in Medicinal Chemistry A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review
Current Cardiology Reviews Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery